2026 Orphan Drugs Report
A safe(r) passage amid stormy waters?
For more than a decade, orphan drugs’ growth has outpaced that of non-orphan prescription drugs. Niche products’ share of worldwide prescription drug sales by value has doubled over the last decade, from less than 10% in 2014 to almost a fifth...
A Safe(r) Passage Amid Stormy Waters?
Policy wins: Priority Review Vouchers Re-Authorized
Big Drugs Will Erode Orphans’ Share of Drug Sales
Top R&D Candidates
Small Molecules Resurgent in Orphan Pipeline
Therapy Area Dynamics Mirror Non-Orphan Pipeline
Orphan Fundamentals Steady
Further Volatility Ahead
How We Help